Back To: Home : Featured Technology : Reagents/Proteins

CLICK HERE FOR WHAT'S NEW IN:
 

First-in-class epigenetic research tools for drug discovery
May 2011
SHARING OPTIONS:


PerkinElmer Inc.
 
PerkinElmer has expanded its epigenetic detection reagents portfolio specifically validated for drug discovery and life sciences research. PerkinElmer's screening assays for epigenetics are built on its homogeneous assay platforms, LANCEUltra detection assays for peptide substrates and AlphaLISA detection assays for both peptide and full-length proteins. Both platforms are no-wash, non-radioactive, antibody-based technologies that offer a unique combination of specificity, sensitivity, dynamic range and throughput. All are validated for mark specificity, providing the sensitivity to work with low substrate and enzyme concentrations, generating robust and highly reproducible assay signals. PerkinElmer's epigenetic and post-translational screening tools now cover nine different histone marks as well as p53, with more than 15 validated enzyme assays to help researchers discover novel drug compounds directed against several epigenetic enzymes, such as histone methyltransferases (HMTs), demethylases (HDMs), acetyltransferases (HATs) and deacetylases (HDACs).
 
PerkinElmer Inc.
(800) 762-4000 
 

Back


PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.